Discover the emerging science in atopic dermatitis (AD) from experts in the field


    ADVANCE 2021 WEBINAR

    Discussions on clinical trial data and real-world experience supporting the use of DUPIXENT in children (6–11) and the psychological burden of AD and how to manage it.

    BAD SYMPOSIUM 2021

    “Experience from two UK centres and implications for treatment in the COVID-19 era”, presented by Professor Carsten Flohr, Dr Hamish Hunter and Dr Richard Woolf.

    BAD SYMPOSIUM 2020

    See what was presented by Dermatologists at the Sanofi-sponsored BAD 2020 symposium, “Clinical experience of DUPIXENT for adults and adolescents with moderate-to-severe AD”.

    PROFESSOR ALAN IRVINE

    The clinical implications of Type 2 inflammation in AD, presented at the Clinical Dermatology Update 2020.
     

    DUPIXENT in adults with moderate-to-severe AD

    DR BEN WALKER

    Discusses the policies that govern access to dupilumab for adolescents with moderate-to-severe AD in the UK.

    SEVERAL EXPERTS

    Discuss how do you define a ‘moderate’ patient – adult or adolescent?
     

    DR TESS MCPHERSON

    Discusses the opportunities and challenges of managing adolescent patients with AD.
     

    TEENA MACKENZIE

    Discusses the role of a Dermatology nurse in managing and supporting adolescents with moderate-to-severe AD and their carers.

    DR TIM CLAYTON

    Discusses the pathophysiology of AD and the treatment options for adolescents with moderate-to-severe disease.

    PROFESSOR MICHAEL CORK

    Discusses the role of DUPIXENT in the treatment of adolescents with moderate-to-severe AD.
     

    DUPIXENT in adults with moderate-to-severe AD

    DR ANTHONY BEWLEY

    Discusses AD and the mind.

     

    PROFESSOR MICHAEL CORK

    Discusses the unmet need in AD.

     

    PROFESSOR ALAN IRVINE

    Discusses the pathophysiology of AD and key DUPXIENT trial data.
     



Reimbursement

Learn about the reimbursement of DUPIXENT in England, Wales and Scotland.





Find out more


Events

Learn more about the upcoming events helping to transform AD for Dermatologists.





Find out more

    AD, atopic dermatitis; BAD, British Association of Dermatologists.

    References

    1. DUPIXENT Summary of Product Characteristics. September 2021.

MAT-IE-2101006(v6.0) | Date of preparation: February 2022